Biopharma manufacturing company Repligen Corporation (NASDAQ: RGEN) will be reporting results this Tuesday before market hours. Here’s what to expect.

Repligen beat analysts’ revenue expectations last quarter, reporting revenues of $188.8 million, up 21.9% year on year. It was a strong quarter for the company, with a solid beat of analysts’ organic revenue estimates and an impressive beat of analysts’ revenue estimates.

Is Repligen a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting Repligen’s revenue to grow 15.1% year on year, improving from its flat revenue in the same quarter last year.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Repligen rarely misses Wall Street’s revenue estimates.

Looking at Repligen’s peers in the drug development inputs & services segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Medpace delivered year-on-year revenue growth of 32%, beating analysts’ expectations by 3.3%, and West Pharmaceutical Services reported revenues up 7.5%, topping estimates by 1.5%. Medpace traded down 15.9% following the results while West Pharmaceutical Services was up 1.8%.

Read our full analysis of Medpace’s results here and West Pharmaceutical Services’s results here.

The outlook for 2025 remains clouded by potential trade policy changes and corporate tax discussions, which could impact business confidence and growth. While some of the drug development inputs & services stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.4% on average over the last month. Repligen is down 16.9% during the same time and is heading into earnings with an average analyst price target of $190.89 (compared to the current share price of $135.74).

Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.